This review highlights recent advances in systemic and immunotherapy for patients with HPV-mediated oropharynx cancer.
Over the last 20 years, therapies have evolved from cytotoxic agents alone to those that target mechanisms of treatment resistance and/or activate the immune system.
This article discusses therapies used in definitive and/or recurrence/metastatic treatment.
For each setting, current standards of care and areas of active clinical investigation are discussed.
